Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.955.2691, or email us at clinicaltrials@nebraskacancer.com.

Download All Current Trials
  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • CRDF-004

    A phase 2, randomized open label study of Onvansertib in combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab vs FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for 1st line treatment in Metastatic Colorectal cancer in patients with a KRAS/NRAS mutation

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Biomarkers: RAS

    Phase: 2

    View Details on ClinicalTrials.gov
  • PCA001 Vaccitech

    A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immnotherapeutic in Men wiht Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer

    Cancer Type: PROSTATE

    Phase: 1

    View Details on ClinicalTrials.gov
  • Boehringer Ingelheim Brightline-2 (1403-0011)

    A Phase 2a/2b, open label, study of BI907828 for treatment of patients with locally advanced/mets, MDM2 amplified, TP53 wild type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

    Cancer Type: Lung NSCLC

    Biomarkers: MDM2, TP53

    Phase: 2

    View Details on ClinicalTrials.gov
  • XL102-101

    Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

    Cancer Type: Solid tumor

    Phase: 1

    View Details on ClinicalTrials.gov
  • XL309-101

    A Phase 1, Open label, multicenter study of Investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of XL309 (ISM3091) as single agent and combination therapy in patients with advanced solid tumors

    Cancer Type: BREAST, PROSTATE, Solid tumor, Peritoneal, Fallopian Tube

    Biomarkers: BRCA

    Phase: 1

    View Details on ClinicalTrials.gov
  • SRF388-101

    Phase 1/1b study of CHS-388 in patients with advanced solid tumors

    Cancer Type: Lung NSCLC

    Lines of Therapy: 3, 2

    Phase: 1,1b

  • VM Oncology, VMO-01C

    Open label, multidose, dose escalation study to investigate the safety, pharmokinetics, and pharmacodynamics of VMC 928 in subjects with solid tumors or lymphoma

    Cancer Type: Solid tumor, Lymphoma

    Biomarkers: TrkA

    Phase: 1

    View Details on ClinicalTrials.gov
  • TPX-0005-07

    A Phase 1/2, Open-label, safety, tolerability, pharmacokinetics, and anti-tumor activity study of repotrectinib in pediatric and young adult subjects with advances or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterations

    Cancer Type: Solid tumor

    Biomarkers: ALK, ROS1, NTRK1-3

    Phase: 2

    View Details on ClinicalTrials.gov
  • TSC-007 (Aadi Precision-1)

    A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

    Cancer Type: Solid tumor

    Biomarkers: TSC1, TSC2

    Phase: 2

    View Details on ClinicalTrials.gov
  • Tempus Aries, TP-CA-007

    Biobank Registry Platform Study of Oncology

    Cancer Type: Colorectal, Pancreatic, Lung NSCLC

    Biomarkers: KRAS

#caringforthegoodlife

Meet DOT.

Skip to content